Aktis Oncology, Inc.
Healthcare
NASDAQ:AKTS · NASDAQ Global Select
Market Cap $1.29B Beta 1.10 P/E (TTM) -28.7
$24.09 +0.47%
+$0.11 today
52W Low $14.72High $29.16
Vol 0.55M · Avg 0.33M
EPS (TTM) -$0.82Biotechnology
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:AKTS · Revenue to Net Income
No earnings data available.
Income Statement
Annual data · 4 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $6.5M +336.9% | $1.5M | $0 | $0 | $1.0B | $809.6M | $921.6M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $344.8M | $725.6M | $804.0M |
| Gross Profit | $6.5M +336.9% | $1.5M | $0 | $0 | $10.3B | $8.9B | $7.6B |
| Gross Margin | 100.0% +0.0pp | 100.0% | — | — | 45.5% | 9.8% | 28.9% |
| Research & Development | $67.5M +64.7% | $41.0M +58.0% | $25.9M +81.2% | $14.3M | $378.4M | $983.2M | $1.3B |
| Selling, General & Admin | $12.6M +11.4% | $11.3M +47.2% | $7.7M +50.4% | $5.1M | $1.4B | $620.6M | $923.0M |
| Operating Expenses | $81.2M +51.6% | $53.5M +53.9% | $34.8M +76.0% | $19.8M | $3.6B | $5.3B | $7.0B |
| Depreciation & Amortization | $2.3M +47.9% | $1.6M +31.7% | $1.2M +168.8% | $445.0K | $1.2B | $374.2M | $1.2B |
| EBITDA | -$61.4M -44.8% | -$42.4M -54.5% | -$27.4M -57.0% | -$17.5M | $12.6B | -$15.2B | $6.8B |
| EBITDA Margin | -945.1% +1906.6pp | -2851.7% | — | — | 10.0% | 5.6% | 46.3% |
| Operating Income | -$74.7M -43.5% | -$52.0M -49.6% | -$34.8M -76.0% | -$19.8M | $10.6B | $12.3B | $14.0B |
| Operating Margin | -1149.5% +2350.8pp | -3500.3% | — | — | 18.7% | 16.6% | 24.1% |
| Interest Income | $11.0M +35.9% | $8.1M +50.7% | $5.4M +226.5% | $1.6M | $1.3B | -$1.5B | -$1.6B |
| Interest Expense | $0 | $0 | $0 | $0 | $969.2M | $1.1B | $1.0B |
| Other Income / Expenses | $11.0M +35.7% | $8.1M +31.2% | $6.2M +235.3% | $1.8M | -$1.6B | -$1.5B | $1.4B |
| Income Before Tax | -$63.7M -44.9% | -$44.0M -53.6% | -$28.6M -59.7% | -$17.9M | -$15.6B | $3.3B | $4.9B |
| Pre-Tax Margin | -980.9% +1976.7pp | -2957.6% | — | — | 13.3% | 20.8% | 18.7% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $666.8M | $1.3B | -$1.6B |
| Net Income | -$63.7M -44.9% | -$44.0M -53.6% | -$28.6M -59.7% | -$17.9M | $5.0B | $4.9B | $4.8B |
| Net Margin | -980.9% +1976.7pp | -2957.6% | — | — | 7.4% | 12.4% | 17.5% |
| EPS (Basic) | -$1 +5.6% | -$1 -53.7% | -$1 -60.8% | -$1 | $1.2B | $400.8M | $703.2M |
| EPS (Diluted) | -$1 +5.6% | -$1 -53.7% | -$1 -60.8% | -$1 | $620.6M | $766.2M | $609.4M |
| Weighted Avg Shares | $52.5M +50.6% | $34.9M +0.0% | $34.9M +0.0% | $34.9M | $892.2M | $757.8M | $925.8M |
| Weighted Avg Shares (Diluted) | $52.5M +50.6% | $34.9M +0.0% | $34.9M +0.0% | $34.9M | $319.6M | $1.2B | $924.4M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
No competitor data available.
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does AKTS generate?
Aktis Oncology, Inc. (AKTS) reported $6.50M of revenue in fiscal 2025.
Is AKTS profitable?
Aktis Oncology, Inc. (AKTS) reported -$63,731,000.00 of net income, with a net margin of -980.9%.
Explore More
Continue the stock analysis
Jump to another research area for this company.
OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.FilingsOpen recent filings alongside price history for deeper research.